US stock · figures in US dollars · scored on full-year results
Vertex Pharmaceuticals Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals scores 50/100 on fundamentals: in the bottom 40% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (100/100); its weakest is Price Fairness (0/100). It carries 3 warning flags: Weak Spot, Profit Spike, Recent Loss.
- Carries a Weak Spot flag
- Carries a Profit Spike flag
- Carries a Recent Loss flag
A financially strong, expensively priced stock, but price fairness needs attention.
Nearby peers
Ranks #39 of 60 in Healthcare by score
One-Minute Summary
Why Vertex Pharmaceuticals scores 50
A financially strong, expensively priced stock, but price fairness needs attention.
Business Strength
60Why 60?
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales grew about 34.4% over 4 years: customers keep spending more with this company.
The company lost money in recent years: the bars below zero are losses, not profits.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales grew about 20.3% over the last 8 quarters: customers keep spending more with this company.
Profit has moved sideways over the last 8 quarters.
Financial Safety
100Why 100?
Show 2 charts
Debt vs Equity, with D/E ratio
Borrowings grew about 125.7% over 4 years: watch this; rising debt adds pressure in bad times.
Short-term assets vs bills, with Current Ratio
Cash & Dividends
50Why 50?
Show 3 charts
Operating vs Free Cash Flow
Cash keeps coming in, though unevenly: fine, but worth keeping an eye on.
Cash vs Total Debt
Dividends per Share, with Yield
Dividends per share have been maintained or raised: management shares the rewards with you.
Price FairnessLowest pillar
0Why 0?
Show chart
Share Price: Weekly Closes (not part of the score)
The share price is up about 31.3% over the past year.
Risk
42Why 42?
Show chart
Revenue vs Inventory, with Inventory % of Revenue
Sector peers
Vertex Pharmaceuticals (VRTX) scores 50/100 (Okay) on Score Your Stock's educational fundamentals model: in the bottom 40% of 503 scored S&P 500 stocks.
Its strongest pillar is Financial Safety (100/100); its weakest is Price Fairness (0/100).
Vertex Pharmaceuticals ranks #39 of 60 scored Healthcare stocks on Score Your Stock.
Vertex Pharmaceuticals (VRTX) has not paid a dividend in the last 12 months.
From Malaysia, open an account with a broker that offers US shares (many local and app-based brokers do), convert ringgit to US dollars, then buy VRTX. US shares trade one share at a time, not in lots of 100. Check the currency conversion fee and US dividend tax (usually 30% withheld for Malaysians) before you buy.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk. It uses the same rules as our Bursa scores. For banks, Financial Safety checks nonaccrual (impaired) loans, loan loss coverage and the CET1 capital ratio, from the FDIC call report of the group's main bank. Full methodology and the default weights: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
Vertex Pharmaceuticals (VRTX) is a Healthcare company (Biotechnology). On Score Your Stock's fundamentals check, it scores 50/100, rated Okay. Its biggest strength is Financial Safety (100/100); its main watch-out is Price Fairness (0/100). Shares currently cost about 36 years of its current profit to buy (P/E 35.9×). Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/us/vrtx-vertex-pharmaceuticals
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Total Debt | Short-Term Debt | Equity | Current Assets | Current Liabilities | Total Assets | Total Liabilities | Inventory | Dividends | Return on Equity (ROE) | Net Profit Margin | Debt-to-Equity | Current Ratio | Interest Coverage | Div yield | P/E Ratio | P/B Ratio | PEG Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | US$ 12.0b | US$ 4.0b | US$ 3.6b | US$ 3.2b | US$ -437.6m | US$ 5.1b | US$ 2.0b | US$ 77.3m | US$ 18.7b | US$ 11.2b | US$ 3.9b | US$ 25.6b | US$ 7.0b | US$ 1.7b | US$ 0.0m | 21% | 33% | 0.1× | 2.9× | 350.1× | 0% | 29.1× | 6.2× | - |
| 2024 | US$ 11.0b | US$ -535.6m | US$ -492.6m | US$ -978.0m | US$ -485.4m | US$ 4.6b | US$ 1.7b | US$ 87.1m | US$ 16.4b | US$ 9.6b | US$ 3.6b | US$ 22.5b | US$ 6.1b | US$ 1.2b | US$ 0.0m | -3% | -5% | 0.1× | 2.7× | 9.1× | 0% | -195.3× | 6.4× | - |
| 2023 | US$ 9.9b | US$ 3.6b | US$ 3.5b | US$ 3.3b | US$ -258.4m | US$ 10.4b | US$ 808.4m | US$ 83.7m | US$ 17.6b | US$ 14.1b | US$ 3.5b | US$ 22.7b | US$ 5.1b | US$ 738.8m | US$ 0.0m | 21% | 37% | 0.1× | 4.0× | 100.3× | 0% | 29.0× | 6.0× | 3.2 |
| 2022 | US$ 8.9b | US$ 3.3b | US$ 4.1b | US$ 3.9b | US$ -204.7m | US$ 10.5b | US$ 899.7m | US$ 89.4m | US$ 13.9b | US$ 13.2b | US$ 2.7b | US$ 18.2b | US$ 4.2b | US$ 460.6m | US$ 0.0m | 24% | 37% | 0.1× | 4.8× | 78.2× | 0% | 22.3× | 5.3× | - |